SCHEMBL3269233

SCHEMBL3269233

Cc1noc(NC(=O)N2CCN(c3cccc(-c4ccc(F)cc4F)c3)CC2)c1C

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
FAAH O00519 10/20 0.49
SCD O00767 1/20 0.43
MAPT P10636 3/20 0.43
TP53 P04637 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
ALDH1A1 P00352 1/20 0.42
PKM P14618 1/20 0.42
DGAT1 O75907 1/20 0.42
POLB P06746 1/20 0.41
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA9 Q16790 1/20 0.40
TSHR P16473 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
KISS1R Q969F8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3268325 0.88 FAAH (0.62) FAAHMAPTTP53SMN1; SMN2ALDH1A1
SCHEMBL3269574 0.88 DGAT1 (0.44) FAAHSCDMAPTSMN1; SMN2ALDH1A1
SCHEMBL3269227 0.85 FAAH (0.63) FAAHMAPTTP53SMN1; SMN2ALDH1A1
SCHEMBL3273330 0.85 FAAH (0.63) FAAHALDH1A1PKMDGAT1
SCHEMBL3442740 0.85 USP2 (0.52) FAAHSCDMAPTSMN1; SMN2ALDH1A1
SCHEMBL3272478 0.84 FAAH (0.50) FAAHSCDMAPTTP53SMN1; SMN2
SCHEMBL3274651 0.83 FAAH (0.63) FAAHALDH1A1PKMDGAT1
SCHEMBL3268551 0.80 FAAH (0.53) FAAHSCDMAPTTP53SMN1; SMN2
SCHEMBL3442823 0.80 USP2 (0.42) FAAHSCDMAPTSMN1; SMN2ALDH1A1
SCHEMBL3268951 0.80 GLA (0.63) FAAHMAPTTP53POLBCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100234389-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-16 US disclosed
US-20100234389-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-16 US disclosed
US-20100234389-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-16 US disclosed
EP-2199282-A1 AMIDE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-06-23 EP disclosed
US-20090163508-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-25 US disclosed
US-20090163508-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-25 US disclosed
US-20090163508-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234389-A1 AMIDE COMPOUND FAAH, FAAH2, NAAA FAAH 1/4885SCD 656/4885MAPT 3707/4885
US-20090163508-A1 AMIDE COMPOUND FAAH, FAAH2, NAAA FAAH 1/4885SCD 656/4885MAPT 3707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.